Since its introduction in 1981, @entity298 ( @entity298 ) has become firmly established as an effective mode of renal replacement therapy and serves an increasing @entity1 population in Korea. The latest registry data indicate that about 3700 end-stage @entity8 @entity1 are maintained on chronic @entity298 , representing 24.1% of the country's dialysis population. The majority (93.3%) of these @entity1 are on continuous ambulatory @entity298 (CAPD) using the two-bag disconnect system, while only 3.3% are on automated @entity298 . Under current renal reimbursement policies, most dialysis @entity1 have to pay 20% of dialysis fees. Thus CAPD @entity1 on 4 x 2-L daily exchanges pay about US 200 per month, not including medication and travel costs. Traditionally, most @entity298 centers in Korea have used the "standard" prescription of 4 exchanges of 2 L of solution for most of their @entity1 . A recent survey of 1467 @entity1 who commenced CAPD in 1997 revealed that 84% of these @entity1 were initially prescribed 4 x 2-L exchanges, while 12% were given a daily volume of 6 L. With this standard prescription, the percentages of Korean CAPD @entity1 initially achieving the adequacy target of Kt/V @entity1133 > or = 2.0 and standardized @entity1011 clearance (SCCr) > or = 60 L/week/1.73 m2, were 74.4% and 82.1%, respectively. It is likely that, among current Korean CAPD @entity1 , a much lower percentage will achieve the clearance targets compared to this initial outcome, but the precise data are not available. However, it is not clear whether the levels of small-solute clearance recommended for optimal @entity298 outcomes, and proposed by the NKF-DOQI guidelines, will bring the expected benefits to Korean @entity1 . Overall survival of @entity298 @entity1 appears to be as good as, or even better than, that in most other countries. Recently, a single large @entity298 center reported @entity1 survival of 92.1%, 85.6%, 81.4%, and 67.6% at 1, 2, 3, and 5 years respectively. Other centers also reported similar outcomes. As in other countries, @entity65 predominate among Korean @entity1 : @entity204 was due to cardiac causes in 29%, to vascular causes in 21%, and to infectious causes in 24%. @entity298 is the most important barrier to prolonged use of CAPD in Korea, and more @entity298 @entity1 transfer to hemodialysis because of @entity298 than in other countries. To further reduce the morbidity and mortality of @entity298 @entity1 , various control measures need to be implemented that can reduce or prevent @entity298 and other infectious complications. Also, to further improve long-term @entity1 outcome, Korean nephrologists need to establish and practice optimal clearance targets in the chronic care of these @entity1 .

Current status of XXXX in Korea: efforts to achieve optimal outcome.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal disease'] @entity1133 :: ('MESH:D014508', 'Chemical') :: ['urea'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular deaths'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity298 :: ('MESH:D010538', 'Disease') :: ['peritoneal dialysis', 'Peritonitis', 'PD', 'Korean PD', 'peritonitis']
@entity298 :: (MESH:D010538,Disease) :: ['peritoneal dialysis']
